Anjum Zauraiz, Iyer Charoo, Naz Sidra, Jaiswal Vikash, Nepal Gaurav, Laguio-Vila Maryrose, Anandaram Sanjay, Thapaliya Sahil
Rochester General Hospital Rochester New York USA.
Harvard Medical School Boston Massachusetts USA.
Clin Case Rep. 2022 Apr 14;10(4):e05733. doi: 10.1002/ccr3.5733. eCollection 2022 Apr.
Guillain-Barre syndrome (GBS) is an acquired inflammatory polyradiculoneuropathy that often follows infection with a virus or bacteria and in rare occasions, vaccination may precede GBS. We present a case of 80-year-old male patient who presented with chief complaints of progressive, ascending bilateral lower extremity paresthesia and weakness following first dose of Moderna vaccine. His symptoms got exacerbated after 2nd dose. Clinical examination and investigation findings including lumbar puncture, nerve conduction study, and electromyography were consistent with the diagnosis of GBS. The patient received treatment with intravenous immunoglobulin and there was significant improvement toward the end of 5th day. Though rare, this case report suggest that physician should remain vigilant for GBS following COVID-19 vaccination.
吉兰-巴雷综合征（GBS）是一种获得性炎性多发性神经根神经病，常继发于病毒或细菌感染，在极少数情况下，接种疫苗可能先于GBS出现。我们报告一例80岁男性患者，其在接种第一剂Moderna疫苗后，以进行性、上行性双侧下肢感觉异常和无力为主诉就诊。第二剂接种后症状加重。临床检查及包括腰椎穿刺、神经传导研究和肌电图在内的检查结果均符合GBS的诊断。患者接受了静脉注射免疫球蛋白治疗，在第5天结束时病情有显著改善。尽管罕见，但本病例报告提示医生在新冠病毒疫苗接种后应警惕GBS。
